Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 1
Submit an article Journal homepage
129
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived

Sara Farshchi ZarabiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaORCID Iconhttp://orcid.org/0000-0003-3478-9663View further author information
ORCID Icon,
Steven ChanPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Vikas GuptaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Dina KhalafPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Andrzej LutynskiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Mark D. MindenPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Amr RostomPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Anna RydlewskiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Andre C. SchuhPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Hassan SibaiPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
,
Karen W. L. YeePrincess Margaret Cancer Centre, Toronto, Ontario, CanadaView further author information
&
Aaron D. SchimmerPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaCorrespondence[email protected]
View further author information
 show all
Pages 237-240 | Received 17 Jan 2017, Accepted 22 Apr 2017, Published online: 09 Jun 2017
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1323273.

Additional information

Funding

V.G. received consultancy fee, honoraria and research funding from Novartis, and honoraria and research funding from Incyte Corporation. A.C.S. reported membership on an entity’s Board of Directors or advisory committees of Amgen. K.Y. received research funding from and reported membership on an entity’s Board of Directors or advisory committees of Novartis Canada. A.D.S. received honoraria from Novartis. A.D.S. holds the Baker chair in leukemia and related diseases. Other authors have no conflicts of interest to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.